42.98 USD
+0.01 (+0.02%)
42.97 USD
-0.01 (-0.02%)
Taking everything into account, SYNH scores 4 out of 10 in our fundamental rating. SYNH was compared to 58 industry peers in the Life Sciences Tools & Services industry. While SYNH is still in line with the averages on profitability rating, there are concerns on its financial health. SYNH scores decently on growth, while it is valued quite cheap. This could make an interesting combination.
1. Profitability
1.1 Basic Checks
SYNH had positive earnings in the past year.
In the past year SYNH had a positive cash flow from operations.
SYNH had positive earnings in each of the past 5 years.
In the past 5 years SYNH always reported a positive cash flow from operatings.
1.2 Ratios
SYNH's Return On Assets of 0.88% is fine compared to the rest of the industry. SYNH outperforms 70.31% of its industry peers.
Looking at the Return On Equity, with a value of 2.04%, SYNH is in the better half of the industry, outperforming 71.88% of the companies in the same industry.
With a decent Return On Invested Capital value of 4.23%, SYNH is doing good in the industry, outperforming 70.31% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for SYNH is significantly below the industry average of 13.53%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.88% | ||
| ROE | 2.04% | ||
| ROIC | 4.23% |
ROA(3y)2.83%
ROA(5y)2.12%
ROE(3y)6.82%
ROE(5y)5.13%
ROIC(3y)4.99%
ROIC(5y)4.67%
1.3 Margins
SYNH has a better Profit Margin (1.31%) than 70.31% of its industry peers.
SYNH's Profit Margin has improved in the last couple of years.
With a decent Operating Margin value of 6.33%, SYNH is doing good in the industry, outperforming 65.63% of the companies in the same industry.
SYNH's Operating Margin has improved in the last couple of years.
The Gross Margin of SYNH (22.14%) is worse than 84.38% of its industry peers.
In the last couple of years the Gross Margin of SYNH has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.33% | ||
| PM (TTM) | 1.31% | ||
| GM | 22.14% |
OM growth 3Y5.34%
OM growth 5Y13.1%
PM growth 3Y20.73%
PM growth 5YN/A
GM growth 3Y1.57%
GM growth 5Y0.02%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), SYNH is destroying value.
SYNH has less shares outstanding than it did 1 year ago.
The debt/assets ratio for SYNH has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.46, we must say that SYNH is in the distress zone and has some risk of bankruptcy.
SYNH's Altman-Z score of 1.46 is in line compared to the rest of the industry. SYNH outperforms 43.75% of its industry peers.
The Debt to FCF ratio of SYNH is 16.71, which is on the high side as it means it would take SYNH, 16.71 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 16.71, SYNH is doing good in the industry, outperforming 65.63% of the companies in the same industry.
A Debt/Equity ratio of 0.77 indicates that SYNH is somewhat dependend on debt financing.
SYNH has a worse Debt to Equity ratio (0.77) than 79.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.77 | ||
| Debt/FCF | 16.71 | ||
| Altman-Z | 1.46 |
ROIC/WACC0.39
WACC10.92%
2.3 Liquidity
A Current Ratio of 1.20 indicates that SYNH should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.20, SYNH is doing worse than 93.75% of the companies in the same industry.
A Quick Ratio of 1.20 indicates that SYNH should not have too much problems paying its short term obligations.
SYNH's Quick ratio of 1.20 is on the low side compared to the rest of the industry. SYNH is outperformed by 82.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.2 | ||
| Quick Ratio | 1.2 |
3. Growth
3.1 Past
The earnings per share for SYNH have decreased strongly by -23.79% in the last year.
SYNH shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.74% yearly.
Looking at the last year, SYNH shows a small growth in Revenue. The Revenue has grown by 0.01% in the last year.
SYNH shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.08% yearly.
EPS 1Y (TTM)-23.79%
EPS 3Y13.48%
EPS 5Y13.74%
EPS Q2Q%-54.4%
Revenue 1Y (TTM)0.01%
Revenue growth 3Y4.87%
Revenue growth 5Y15.08%
Sales Q2Q%0.39%
3.2 Future
The Earnings Per Share is expected to grow by 3.17% on average over the next years.
Based on estimates for the next years, SYNH will show a small growth in Revenue. The Revenue will grow by 1.71% on average per year.
EPS Next Y-25.43%
EPS Next 2Y-6.79%
EPS Next 3Y-1.2%
EPS Next 5Y3.17%
Revenue Next Year-2.82%
Revenue Next 2Y-0.54%
Revenue Next 3Y1.03%
Revenue Next 5Y1.71%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 11.37, the valuation of SYNH can be described as very reasonable.
SYNH's Price/Earnings ratio is rather cheap when compared to the industry. SYNH is cheaper than 100.00% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.11, SYNH is valued rather cheaply.
With a Price/Forward Earnings ratio of 10.48, the valuation of SYNH can be described as very reasonable.
SYNH's Price/Forward Earnings ratio is rather cheap when compared to the industry. SYNH is cheaper than 100.00% of the companies in the same industry.
SYNH is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.21, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.37 | ||
| Fwd PE | 10.48 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, SYNH is valued cheaper than 95.31% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, SYNH is valued cheaply inside the industry as 85.94% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 27.53 | ||
| EV/EBITDA | 12.05 |
4.3 Compensation for Growth
The decent profitability rating of SYNH may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.83
EPS Next 2Y-6.79%
EPS Next 3Y-1.2%
5. Dividend
5.1 Amount
SYNH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
42.98
+0.01 (+0.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners0%
Inst Owner Change0%
Ins Owners0.49%
Ins Owner Change0%
Market Cap4.46B
Revenue(TTM)5.42B
Net Income(TTM)71.22M
Analysts53.75
Price Target43.35 (0.86%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-9.02%
Min EPS beat(2)-29.57%
Max EPS beat(2)11.52%
EPS beat(4)2
Avg EPS beat(4)-6.43%
Min EPS beat(4)-29.57%
Max EPS beat(4)11.52%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.57%
Min Revenue beat(2)3.81%
Max Revenue beat(2)5.33%
Revenue beat(4)3
Avg Revenue beat(4)1.96%
Min Revenue beat(4)-4.69%
Max Revenue beat(4)5.33%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.13%
EPS NQ rev (1m)-1.52%
EPS NQ rev (3m)0.41%
EPS NY rev (1m)1.03%
EPS NY rev (3m)4.38%
Revenue NQ rev (1m)0.31%
Revenue NQ rev (3m)1.89%
Revenue NY rev (1m)0.55%
Revenue NY rev (3m)2.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.37 | ||
| Fwd PE | 10.48 | ||
| P/S | 0.82 | ||
| P/FCF | 27.53 | ||
| P/OCF | 17.62 | ||
| P/B | 1.28 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.05 |
EPS(TTM)3.78
EY8.79%
EPS(NY)4.1
Fwd EY9.54%
FCF(TTM)1.56
FCFY3.63%
OCF(TTM)2.44
OCFY5.67%
SpS52.25
BVpS33.68
TBVpS-19.54
PEG (NY)N/A
PEG (5Y)0.83
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.88% | ||
| ROE | 2.04% | ||
| ROCE | 5.32% | ||
| ROIC | 4.23% | ||
| ROICexc | 4.29% | ||
| ROICexgc | 32.26% | ||
| OM | 6.33% | ||
| PM (TTM) | 1.31% | ||
| GM | 22.14% | ||
| FCFM | 2.99% |
ROA(3y)2.83%
ROA(5y)2.12%
ROE(3y)6.82%
ROE(5y)5.13%
ROIC(3y)4.99%
ROIC(5y)4.67%
ROICexc(3y)5.11%
ROICexc(5y)4.79%
ROICexgc(3y)50.55%
ROICexgc(5y)76.43%
ROCE(3y)6.27%
ROCE(5y)5.87%
ROICexgc growth 3Y-8.19%
ROICexgc growth 5Y1.51%
ROICexc growth 3Y6.95%
ROICexc growth 5Y27.79%
OM growth 3Y5.34%
OM growth 5Y13.1%
PM growth 3Y20.73%
PM growth 5YN/A
GM growth 3Y1.57%
GM growth 5Y0.02%
F-Score6
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.77 | ||
| Debt/FCF | 16.71 | ||
| Debt/EBITDA | 4.56 | ||
| Cap/Depr | 37.2% | ||
| Cap/Sales | 1.68% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 43.05% | ||
| Profit Quality | 227.34% | ||
| Current Ratio | 1.2 | ||
| Quick Ratio | 1.2 | ||
| Altman-Z | 1.46 |
F-Score6
WACC10.92%
ROIC/WACC0.39
Cap/Depr(3y)28.14%
Cap/Depr(5y)26.15%
Cap/Sales(3y)1.32%
Cap/Sales(5y)1.31%
Profit Quality(3y)162.48%
Profit Quality(5y)341.03%
High Growth Momentum
Growth
EPS 1Y (TTM)-23.79%
EPS 3Y13.48%
EPS 5Y13.74%
EPS Q2Q%-54.4%
EPS Next Y-25.43%
EPS Next 2Y-6.79%
EPS Next 3Y-1.2%
EPS Next 5Y3.17%
Revenue 1Y (TTM)0.01%
Revenue growth 3Y4.87%
Revenue growth 5Y15.08%
Sales Q2Q%0.39%
Revenue Next Year-2.82%
Revenue Next 2Y-0.54%
Revenue Next 3Y1.03%
Revenue Next 5Y1.71%
EBIT growth 1Y-27.25%
EBIT growth 3Y10.47%
EBIT growth 5Y30.16%
EBIT Next Year-2.87%
EBIT Next 3Y4.37%
EBIT Next 5Y3.5%
FCF growth 1Y-63.52%
FCF growth 3Y9.43%
FCF growth 5Y16.65%
OCF growth 1Y-47.97%
OCF growth 3Y10.26%
OCF growth 5Y16.58%
SYNEOS HEALTH INC / SYNH FAQ
What is the ChartMill fundamental rating of SYNEOS HEALTH INC (SYNH) stock?
ChartMill assigns a fundamental rating of 5 / 10 to SYNH.
Can you provide the valuation status for SYNEOS HEALTH INC?
ChartMill assigns a valuation rating of 7 / 10 to SYNEOS HEALTH INC (SYNH). This can be considered as Undervalued.
Can you provide the profitability details for SYNEOS HEALTH INC?
SYNEOS HEALTH INC (SYNH) has a profitability rating of 6 / 10.
What is the valuation of SYNEOS HEALTH INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for SYNEOS HEALTH INC (SYNH) is 11.37 and the Price/Book (PB) ratio is 1.28.
What is the earnings growth outlook for SYNEOS HEALTH INC?
The Earnings per Share (EPS) of SYNEOS HEALTH INC (SYNH) is expected to decline by -25.43% in the next year.